cbdMD, Inc. Secures Significant Investment in Series C Financing
cbdMD, Inc. (NYSE American: YCBD), a prominent name in the wellness sector and owner of a variety of health-focused products, has successfully concluded a Series C Convertible Preferred Stock private placement. This recent financial maneuver garnered the company $2.25 million from institutional investors. This substantial investment reflects the increasing confidence in cbdMD's commitment to enhancing its product offerings and expanding its market presence.
Details of the Series C Preferred Stock
Through the securities purchase agreements, cbdMD has issued 1,000,000 shares of Series C Convertible Preferred Stock. The gross proceeds from this initiative are approximately $2.25 million, with expected net proceeds around $2.1 million. The net proceeds will primarily be allocated for working capital and support the ongoing strategic initiatives of the company.
The Series C shares come with an attractive 10% annual dividend and are convertible at the holder's option to common stock at a conversion price of $2.25 per share. This arrangement includes anti-dilution protections designed to safeguard investors as the company continues its expansion.
CEO's Insights on Financial Strategy
Ronan Kennedy, the Chief Executive Officer and Chief Financial Officer of cbdMD, highlighted the importance of this funding round. "We are pleased to continue strengthening our balance sheet to assist the Company's ongoing initiatives to expand distribution for its consumer brands, and position cbdMD for sustained profitability," he stated. This initiative is part of cbdMD's broader strategy to fortify its market positioning amid growing competition in the wellness industry.
About cbdMD, Inc.
cbdMD, Inc. is recognized for its comprehensive range of U.S.-produced, hemp-derived cannabinoid products, which include not just CBD but also other compounds like CBG and CBN. Among its innovative products are:
Herbal Oasis
a unique hemp-derived THC social seltzer that aims to redefine social connections and provide a relaxed drinking experience.
ATRx Labs
which features functional mushroom supplements designed to enhance focus, calmness, and overall vitality.
Paw CBD
a trusted name in CBD products for pets, ensuring that pet owners can provide their companions with the best quality health options.
cbdMD is dedicated to quality, transparency, and innovation in the wellness sector. The company distributes its products widely, both through online platforms and retail partners across the United States. For more information about cbdMD's products, please visit their official websites.
Frequently Asked Questions
What is the purpose of the $2.25 million raised?
The funds will be used primarily for working capital and to support ongoing strategic initiatives.
What is the annual dividend rate on the Series C shares?
The Series C shares have an attractive 10% annual dividend rate.
What brands does cbdMD, Inc. own?
cbdMD operates several brands, including Herbal Oasis, ATRx Labs, and Paw CBD.
Who is the CEO of cbdMD, Inc.?
Ronan Kennedy serves as the Chief Executive Officer and Chief Financial Officer of cbdMD.
What does cbdMD specialize in?
cbdMD specializes in a comprehensive line of hemp-derived cannabinoid products aimed at wellness and health.
